These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31855154)

  • 21. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease and anemia: intravenous iron treatment.
    Kangaspunta M; Haapamäki J; Färkkilä M; Arkkila P
    Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
    Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J;
    J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous versus oral iron for anaemia among pregnant women in Nigeria (IVON): an open-label, randomised controlled trial.
    Afolabi BB; Babah OA; Adeyemo TA; Balogun M; Banke-Thomas A; Abioye AI; Akinajo OR; Galadanci HS; Quao RA; Adelabu H; Sam-Agudu NA; Adaramoye VO; Abubakar A; Banigbe B; Olorunfemi G; Beňová L; Larsson EC; Annerstedt KS; Hanson C; Thornton J;
    Lancet Glob Health; 2024 Oct; 12(10):e1649-e1659. PubMed ID: 39304237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

  • 30. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
    Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
    Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
    Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
    Froessler B; Gajic T; Dekker G; Hodyl NA
    Arch Gynecol Obstet; 2018 Jul; 298(1):75-82. PubMed ID: 29740690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
    Steinmetz T; Tschechne B; Harlin O; Klement B; Franzem M; Wamhoff J; Tesch H; Rohrberg R; Marschner N
    Ann Oncol; 2013 Feb; 24(2):475-482. PubMed ID: 23071262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
    Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R
    Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferric carboxymaltose: a review of its use in iron deficiency.
    Keating GM
    Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.
    Hedenus M; Karlsson T; Ludwig H; Rzychon B; Felder M; Roubert B; Birgegård G
    Med Oncol; 2014 Dec; 31(12):302. PubMed ID: 25373320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.